| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $909,237,629 | 76 | 100 |
| Humes Jennifer | Chief Accounting Officer | 0 | $0 | 1 | $384,073 | $-384,073 |
| Epperly Melissa B, | director | 0 | $0 | 4 | $2.65M | $-2.65M |
| Fitzgerald Meghan | director | 0 | $0 | 4 | $3.27M | $-3.27M |
| Pulik Richard | CFO | 0 | $0 | 1 | $9.12M | $-9.12M |
| Gline Matthew | CEO | 0 | $0 | 2 | $46.17M | $-46.17M |
| Torti Frank | President and Vant Chair | 0 | $0 | 3 | $82.04M | $-82.04M |
| Venker Eric | President & Immunovant CEO | 0 | $0 | 15 | $84.14M | $-84.14M |
| Ramaswamy Vivek | 10 percent owner | 0 | $0 | 6 | $105.88M | $-105.88M |
| Sukhatme Mayukh | President & CIO | 0 | $0 | 12 | $109.13M | $-109.13M |
| QVT Financial LP | Director by Deputization | 0 | $0 | 9 | $147.38M | $-147.38M |
| MANCHESTER KEITH S | director | 0 | $0 | 9 | $154.47M | $-154.47M |
| Gold Daniel Allen | director | 0 | $0 | 10 | $164.59M | $-164.59M |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic …
Over the last 12 months, insiders at Roivant Sciences Ltd. have bought $0 and sold $909.24M worth of Roivant Sciences Ltd. stock.
On average, over the past 5 years, insiders at Roivant Sciences Ltd. have bought $13.44M and sold $531.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,315 shares for transaction amount of $49,957 was made by Gline Matthew (CEO) on 2025‑09‑18.
| 2026-10-28 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0273% | $36.59 | $7.32M | -1.71% | |
| 2026-10-20 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0278% | $35.11 | $7.02M | +5.01% | |
| 2026-10-01 | Sale | Epperly Melissa B, | director | 17,750 0.0025% | $36.10 | $640,861 | +0.62% | |
| 2026-09-30 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0277% | $36.62 | $7.32M | -2.58% | |
| 2026-09-15 | Sale | Fitzgerald Meghan | director | 5,112 0.0007% | $39.74 | $203,152 | -8.73% | |
| 2026-09-15 | Sale | Epperly Melissa B, | director | 4,938 0.0007% | $39.74 | $196,230 | -8.73% | |
| 2026-09-08 | Sale | Fitzgerald Meghan | director | 20,000 0.0027% | $39.90 | $798,000 | -12.02% | |
| 2026-08-28 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0286% | $35.77 | $7.15M | +3.98% | |
| 2026-08-21 | Sale | Sukhatme Mayukh | President & CIO | 144,756 0.0201% | $36.48 | $5.28M | +0.17% | |
| 2026-08-20 | Sale | Sukhatme Mayukh | President & CIO | 17,519 0.0025% | $37.30 | $653,459 | -1.38% | |
| 2026-08-19 | Sale | Sukhatme Mayukh | President & CIO | 172,899 0.0238% | $37.17 | $6.43M | -2.78% | |
| 2026-08-18 | Sale | Sukhatme Mayukh | President & CIO | 136,942 0.0186% | $36.73 | $5.03M | -2.56% | |
| 2026-08-17 | Sale | Sukhatme Mayukh | President & CIO | 284,707 0.0395% | $36.25 | $10.32M | +0.63% | |
| 2026-08-14 | Sale | Sukhatme Mayukh | President & CIO | 243,177 0.0338% | $36.23 | $8.81M | +0.59% | |
| 2026-07-27 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.028% | $34.95 | $6.99M | +4.10% | |
| 2026-06-30 | Sale | QVT Financial LP | Director by Deputization | 12,380 0.0017% | $35.28 | $436,766 | +1.13% | |
| 2026-06-30 | Sale | Gold Daniel Allen | director | 12,380 0.0017% | $35.28 | $436,766 | +1.13% | |
| 2026-06-30 | Sale | MANCHESTER KEITH S | director | 212,380 0.0301% | $35.44 | $7.53M | +1.13% | |
| 2026-06-30 | Sale | Fitzgerald Meghan | director | 10,000 0.0014% | $34.90 | $349,000 | +1.13% | |
| 2026-06-29 | Sale | QVT Financial LP | Director by Deputization | 800,000 0.1107% | $34.55 | $27.64M | +3.02% |
| Gline Matthew | CEO | 16736116 2.317% | $603.17M | 1 | 14 | +85.09% |
| Dexcel Pharma Technologies Ltd. | director | 102849443 14.2387% | $3.71B | 3 | 0 | +38.64% |
| Oren Dan | 98840843 13.6837% | $3.56B | 1 | 0 | +22.38% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 264 | +80.98% | 107M | +21.33% |
| Decreased Positions | 141 | -43.25% | 97M | -19.41% |
| New Positions | 111 | New | 20M | New |
| Sold Out Positions | 43 | Sold Out | 9M | Sold Out |
| Total Postitions | 449 | +37.73% | 511M | +1.92% |
| Fmr Llc | $1.33M | 8.74% | 60.77M | +5M | +9.47% | 2025-09-30 |
| Morgan Stanley | $972,000.00 | 6.38% | 44.32M | -371,109 | -0.83% | 2025-09-30 |
| Sb Investment Advisers (Uk) Ltd | $884,111.00 | 5.8% | 40.32M | -20M | -32.76% | 2025-09-30 |
| Blackrock, Inc. | $871,167.00 | 5.72% | 39.72M | -591,428 | -1.47% | 2025-09-30 |
| Vanguard Group Inc | $850,992.00 | 5.58% | 38.8M | -521,408 | -1.33% | 2025-09-30 |
| Qvt Financial Lp | $644,339.00 | 4.23% | 29.38M | 0 | 0% | 2025-09-30 |
| Viking Global Investors Lp | $517,435.00 | 3.4% | 23.59M | -11M | -31.09% | 2025-09-30 |
| Rubric Capital Management Lp | $438,600.00 | 2.88% | 20M | -370,336 | -1.82% | 2025-09-30 |
| State Street Corp | $410,094.00 | 2.69% | 18.7M | -1M | -5.43% | 2025-09-30 |
| Patient Square Capital Lp | $273,686.00 | 1.8% | 12.48M | 0 | 0% | 2025-09-30 |